OBJECTIVE: To assess the uptake and acceptability of self-administration of @entity3927 at home for medical abortion in Nepal. METHODS: A prospective, comparative, non-randomized, open-label study was conducted at two hospitals in Kathmandu, Nepal, between November 11, 2009, and January 15, 2011. All @entity1 in good health and aged 18years or older who sought medical abortion after fewer than 64days of pregnancy were enrolled. @entity1 were offered the choice of taking 200mg @entity3927 orally in the clinic or at home; all @entity1 self-administered 400 g of sublingual @entity396 at home 24-72hours later. All @entity1 were scheduled to return to the clinic within 14days of @entity3927 administration for follow-up. RESULTS: Among 200 @entity1 , 144 (72.0%) opted to take the @entity3927 at home. Medical abortion was successful in 130 (95.6%) of 136 @entity1 in the home group who were followed up and 53 (94.6%) of 56 @entity1 in the clinic group. Only 4 (2.9%) @entity1 in the home group took the @entity3927 after the scheduled time. Overall, 133 (97.8%) @entity1 in the home group stated that they would recommend home administration of @entity3927 if a friend wanted a medical abortion. CONCLUSION: Self-administration of @entity3927 outside the clinic should be offered to all @entity1 as part of routine medical abortion services in Nepal. Clinical trials.gov:NCT00994734.

A prospective open-label study of home use of XXXX for medical abortion in Nepal.

@entity1 :: ('9606', 'Species') :: ['participants', 'women', 'Participants'] @entity3927 :: ('MESH:D015735', 'Chemical') :: ['mifepristone'] @entity396 :: ('MESH:D016595', 'Chemical') :: ['misoprostol']
@entity3927 :: (MESH:D015735,Chemical) :: ['mifepristone']
